What changed in ten years and what is newly possible or cheap — lower extremity lymphedema compression therapy

1. Summary

Ten years ago, lower-extremity lymphedema compression technology meant elastic garments, adjustable-strap wraps, and pneumatic pump sleeves; that landscape now includes a fourth, mechanically distinct category. In 2021 the FDA cleared the first non-pneumatic active compression device (NPCD) for lower-extremity use — Koya Medical's Dayspring, 510(k) K210885 — under the same generic device type ("Sleeve, Limb, Compressible," product code JOW, 21 CFR 870.5800) that has covered pneumatic pumps for decades [7][8]. Clearance volume under that generic type has held roughly steady over the decade, but the roster of clearance-holders has broadened to include several China-based manufacturers not previously active in it [9]. The older pneumatic technology (advanced pneumatic compression devices, APCDs) continues to show effectiveness in a 2025 systematic review and meta-analysis and in a Veterans Affairs longitudinal cohort [14][15]. Beyond the NPCD, everything else located this pass — an instrumented sensor-feedback pilot, a soft-robotic sleeve prototype, and an AI/digital-health narrative review — is at the pilot, bench-test, or synthesis stage, not a cleared or marketed product.

2. What Changed

_Baseline (v1). No prior version; this establishes the starting point for future diffs._

3. Details

A new device category: non-pneumatic active compression (2020–2024)

The clearest technology-category change in ten years is not an improvement to compression garments but a mechanically different actuation approach cleared as a class II device under an existing generic type. Koya Medical's Dayspring received 510(k) clearance for lower-extremity use in 2021 (K210885, decided 2021-04-23), a second clearance for the "Dayspring Lite" variant the same year (K212287, decided 2021-09-21), and a further clearance in 2024 (K223228, decided 2024-01-04) [7]. The device's own FDA indications for use describe it as a "prescription only wearable compression system…intended for use in a clinic or home setting" across lymphedema, post-mastectomy edema, venous insufficiency, venous stasis ulcers, and phlebolymphedema, among other conditions [7]. Published work on this device category describes the underlying mechanism as shape-memory-alloy actuation rather than a pneumatic bladder: "Non-pneumatic compression devices (NPCDs) rely on shape-memory alloy technology that allows patients to ambulate and remain active during lymphedema treatment" [4].

In a nine-site, 71-patient (108-limb) randomized crossover trial (TEAYS, NCT05507346, sponsor Koya Medical, Inc.) [3], the tested NPCD produced a mean limb-volume decrease of 369.9 ± 68.19 mL versus 83.1 ± 67.99 mL for a commercially available APCD over a 90-day treatment period (P<.05), with higher reported adherence (81% vs 56%, P<.001) and satisfaction (78% vs 22%) [sponsor-reported][1]. A subanalysis of the same trial's 35 phlebolymphedema patients reported a similarly directional result (424.49 ± 100.9 mL vs 50.8 ± 112.1 mL, P=.0085) [sponsor-reported][2]. A separate, earlier open-label pilot (24 enrolled, 18 completers, non-randomized) reported a 39.4% average reduction in affected-limb edema over 12 weeks with an NPCD [single-source][6]. A small non-randomized study (13 patients, 21 limbs) of foot-and-ankle swelling attributed the effect specifically to shape-memory-alloy actuation and reported significant circumference and volume reduction despite the tested garment "lacking a foot piece" [single-source][4]. A 2026 position statement from the American Venous Forum and the American Venous and Lymphatic Society reviewed this category favorably, describing "two randomized controlled trials" as showing NPCD "superior outcomes over advanced PCDs" and recommending its "inclusion in future lymphedema treatment guidelines" be considered [single-source][5].

Set against this, the older pneumatic technology these trials compare against continues to be reported as effective on its own terms: a systematic review and meta-analysis of 12 studies from a 2010–2021 literature search found APCDs associated with reduced limb volume, reduced cellulitis rates, and reduced reliance on manual lymphatic drainage [14], and a four-site, 179-patient Veterans Affairs longitudinal study reported 72% compliance with APCD use (5–7 days/week) through 52 weeks and a reduction in new cellulitis episodes among patients with a prior episode (21.4% to 6.1%, P=.001) [15].

The incumbent pneumatic-sleeve hardware: a steady clearance rate, a broader roster of entrants

Both the older APCDs and the new NPCD share the same FDA generic type and product code — "Sleeve, Limb, Compressible" (product code JOW, class II, 21 CFR 870.5800) — a regulation that defines the covered device by "inflating periodically a sleeve around the limb" [8][9]. Under that single code, 510(k) clearance volume has stayed in roughly the same range over ten years: 30 clearances from 2016-09-03 to 2019-09-03, 38 from 2019-09-03 to 2022-09-03, 19 from 2022-09-03 to 2025-09-03, and 8 in the year from 2025-09-03 to 2026-09-01 [9]. The clearance-holder roster in the most recent three-year window includes manufacturers headquartered in Shenzhen, Guangzhou, and Suzhou alongside established US and European names, next to the established players [9]. No device recall was found for either of the two most visible companies in this space, Koya Medical or Tactile Medical, across the full ten-year window [10].

Instrumented feedback and soft-robotic prototypes: not yet products

Two published engineering-stage efforts point at a different axis of change — instrumenting the garment itself, independent of the pneumatic-versus-mechanical actuation question above. A 2020 pilot fitted a capacitive pressure sensor into a lymphedema garment's ankle pocket, paired by Bluetooth to a mobile device, and found that clinical staff (n=12, split into two training arms) came closer to a 35 mmHg donning target with real-time sensor feedback (|Ppost−35| = 5 ± 4 mmHg) than with instruction alone (12 ± 12 mmHg, P<.05) [single-source][11]. A 2021 conference paper describes a three-layer "soft robotic sleeve" — pump-inflated pockets of graduated height creating a passive compression profile, monitored by embedded force sensors — bench-tested on healthy volunteers to reach 30/40/50 mmHg target pressures with an approximately 40 mmHg distal-to-proximal gradient [single-source][12]. Neither has a located 510(k) clearance, and neither abstract reports testing on a lymphedema patient population.

AI and digital-health integration: a described direction, not a demonstrated one

A 2025 narrative review frames a broader digital-health direction for the field — AI-driven risk stratification, telehealth, mobile apps, virtual-reality rehabilitation, and "sensor-equipped garments, adaptive pneumatic systems, and vibration-assisted apparatus" — while naming "compliance with regulatory frameworks" as one of several unresolved implementation challenges [single-source][13]. No FDA clearance or trial record for an AI-driven or sensor-based sub-bandage pressure product was located in this pass; the review synthesizes other literature rather than reporting a cleared or marketed device itself.

4. Sources

[1] Results from a comparative study to evaluate the treatment effectiveness of a nonpneumatic compression device vs an advanced pneumatic compression device for lower extremity lymphedema swelling (TEAYS study) — Journal of Vascular Surgery: Venous and Lymphatic Disorders (published 2025-01; accessed 2026-09-01). PMID 39222789 — https://pubmed.ncbi.nlm.nih.gov/39222789/ [peer-reviewed] [2] Use of a Portable, Nonpneumatic Active Compression Device in Treatment of Phlebolymphedema: A TEAYS Subanalysis — Annals of Vascular Surgery (published 2026-07; accessed 2026-09-01). PMID 41850352 — https://pubmed.ncbi.nlm.nih.gov/41850352/ [peer-reviewed] [3] A Clinical Study to Evaluate the Effectiveness of a Novel Portable Non-Pneumatic Active Compression Device vs. an Advanced Pneumatic Compression Device for Treating Lower Extremity Lymphedema — ClinicalTrials.gov (last updated 2025-12-12; accessed 2026-09-01). NCT05507346 — https://clinicaltrials.gov/study/NCT05507346 [trial-registry] [4] A novel non-pneumatic compression device results in reduced foot and ankle swelling in patients with venous and lymphatic edema — Vascular (published 2026-02; accessed 2026-09-01). PMID 39631049 — https://pubmed.ncbi.nlm.nih.gov/39631049/ [peer-reviewed] [5] Non-pneumatic compression and its clinical utility in management of lymphedema. A position statement endorsed by the American Venous Forum and the American Venous and Lymphatic Society — Journal of Vascular Surgery: Venous and Lymphatic Disorders (published 2026-03; accessed 2026-09-01). PMID 41271100 — https://pubmed.ncbi.nlm.nih.gov/41271100/ [guideline] [6] A non-randomized, open-label study of the safety and effectiveness of a novel non-pneumatic compression device (NPCD) for lower limb lymphedema — Scientific Reports (published 2022-08-17; accessed 2026-09-01). PMID 35977981 — https://pubmed.ncbi.nlm.nih.gov/35977981/ [peer-reviewed] [7] 510(k) clearances for the Dayspring product line, Koya Medical, Inc.: K210885 (decided 2021-04-23), K212287 "Dayspring Lite" (decided 2021-09-21), K223228 (decided 2024-01-04); indications for use retrieved directly from the K210885 510(k) summary — openFDA device/510(k) database and FDA 510(k) summary (accessed 2026-09-01). K210885 — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K210885 [federal-registry] [8] 21 CFR 870.5800 — Compressible limb sleeve — eCFR, U.S. Government Publishing Office (issue 2026-08-27; accessed 2026-09-01). 21 CFR 870.5800 — https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-870/subpart-F/section-870.5800 [federal-registry] [9] openFDA 510(k) database, product code JOW ("Sleeve, Limb, Compressible," 21 CFR 870.5800): 30 clearances 2016-09-03–2019-09-03, 38 clearances 2019-09-03–2022-09-03, 19 clearances 2022-09-03–2025-09-03, 8 clearances 2025-09-03–2026-09-01 — U.S. Food & Drug Administration (accessed 2026-09-01). 21 CFR 870.5800 — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm [federal-registry] [10] openFDA device recall database, query recalling_firm:"Koya Medical" and recalling_firm:"Tactile Medical," 2016-09-03 to 2026-09-01: zero matching records — U.S. Food & Drug Administration (accessed 2026-09-01). 21 CFR 870.5800 — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm [federal-registry] [11] Implementing a Wearable Sensor for Lymphedema Garments: A Prospective Study of Training Effectiveness — Wound Management & Prevention (published 2020-01; accessed 2026-09-01). PMID 32459660 — https://pubmed.ncbi.nlm.nih.gov/32459660/ [peer-reviewed] [12] A Soft Robotic Sleeve for Compression Therapy of the Lower Limb — Annual International Conference of the IEEE Engineering in Medicine and Biology Society (published 2021-11; accessed 2026-09-01). PMID 34891519 — https://pubmed.ncbi.nlm.nih.gov/34891519/ [peer-reviewed] [13] Technology-enhanced compression and AI-integrated lymphedema care: a narrative review — Irish Journal of Medical Science (published 2025-12; accessed 2026-09-01). PMID 41182582 — https://pubmed.ncbi.nlm.nih.gov/41182582/ [peer-reviewed] [14] Effect of Advanced Pneumatic Compression Devices in the Treatment of Lymphedema: A Systematic Review and Meta-Analyses — Lymphology (published 2025; accessed 2026-09-01, month not given in the PubMed record). PMID 41406422 — https://pubmed.ncbi.nlm.nih.gov/41406422/ [peer-reviewed] [15] Longitudinal assessment of health-related quality of life and clinical outcomes with at home advanced pneumatic compression treatment of lower extremity lymphedema — Journal of Vascular Surgery: Venous and Lymphatic Disorders (published 2024-07; accessed 2026-09-01). PMID 38636734 — https://pubmed.ncbi.nlm.nih.gov/38636734/ [peer-reviewed]

5. Sourcing & Gaps

Well established: That Koya Medical's Dayspring NPCD is FDA-cleared under 21 CFR 870.5800, product code JOW [7][8][9], and that the older pneumatic technology (APCDs) is effective for lymphedema [14][15], each rest on ≥2 independent primary sources and are stated plainly in section 3.

Thin: Every specific efficacy or adherence comparison between the NPCD and an APCD ([1][2][4][6]) rests on trials that are either directly sponsored by the device's own manufacturer — the TEAYS registry record names Koya Medical, Inc. as sponsor [3] — or are single, non-randomized, open-label studies with no funding statement retrieved. The professional-society position statement [5] is itself a single document built largely on the same sponsor-linked trial family. The sensor-feedback pilot [11] and the soft-robotic prototype [12] are each one small study or bench test. The AI/digital-health narrative review [13] is one document synthesizing other literature, not itself primary evidence of any cleared product.

Rescoped from class 3: None. This report answers what has changed and what is newly cleared, published, or bench-tested in this domain over the past ten years — a class 1 and class 2 question throughout — not what any clinician or patient would adopt.

Out of scope: A patent search for garment-fitting or compression-actuation technology (a USPTO record for "a system for determining production values for a custom-tailored compression garment," found by WebSearch) could not be checked through this repo's patent connector, which requires EPO_OPS_KEY/EPO_OPS_SECRET, unset in this environment — the same credential-gated boundary already named for this directory generally. CPT-level procedure descriptors and HCPCS payment detail for either the NPCD or APCD category were not pursued here; reimbursement is a separate dossier section, outside this report's declared scope.

Not searched vs. not found: Mobile 3D-scanning tools for custom compression-garment fitting were searched for and named commercial products surfaced (a WebSearch turned up named vendors), but two direct-retrieval attempts — a vendor's own product page and the USPTO patent PDF found in the same search — both returned HTTP 403, so nothing from either appears as a finding in section 3. This is not retrieved, not evidence the technology does not exist or is not in use. MAUDE narratives for either the NPCD or APCD product lines were not searched — no connector in this repo reaches MAUDE, the same boundary already on record in this domain's dossier.

[inference] 21 CFR 870.5800 defines the covered generic type by "inflating periodically a sleeve around the limb" [8], yet the same product code (JOW) also covers Koya Medical's Dayspring, which its own 510(k) clearance record and the published literature on the category describe as actuated by shape-memory alloy rather than pneumatic inflation [4][7][9]. Read together, this suggests the generic type's defining regulatory text has not been rewritten to reflect a mechanically distinct actuation approach entering the same regulatory bucket — a reader should not assume that "cleared under 870.5800" implies "operates by periodic inflation."

6. Claim Candidates